Table 2 KIR and HLA gene frequencies, KIR haplotypes, and KIR-HLA ligand combinations in 135 advanced-stage classic HL patients and 221 healthy controls

Activating KIR

 KIR2DS1

72

53.3

97

43.9.

 KIR2DS2

78

57.8

125

56.6

 KIR2DS3

54

40.0

77

34.9

 KIR2DS4

124

91.9

202

91.4

 KIR2DS5

42

31.1

75

33.9

 KIR3DS1

53

39.3

88

39.8

Inhibitory KIR

 KIR2DL1

132

97.8

215

97.2

 KIR2DL2

80

59.2

126

57.0

 KIR2DL3

123

91.1

188

85.0

 KIR2DL4

135

100

221

100

 KIR2DL5

78

57.8

116

52.5

 KIR3DL1

135

100

206

93.2

 KIR3DL2

135

100

219

99.1

 KIR3DL3

135

100

221

100

KIR genotypes

 AA

42

31.1

66

29.9

 Bx

93

68.8

155

70.1

 AA/C1-C1

2

4.8

35

15.7

0.001

0.08 (0.013–0.35)

KIR ligands

 C1 pres

81

60.0

161

72.7

0.014

0.56 (0.35–0.90)

 C2 pres

120

88.9

168

76

0.003

2.5 (1.31–4.90)

 HLA-Bw4 pres

90

66.9

175

79.2

Activating KIR and their ligands

 KIR2DS1 pres/HLA-C2 pres

56

41.5

78

35.3

 KIR2DS1 pres/HLA-C2 abs

16

11.9

19

11.6

 KIR2DS2 pres/HLA-C1 pres

46

34.1

80

36.2

 KIR2DS2 pres/HLA-C1 abs

32

23.7

45

20.4

 KIR3DS1 pres/HLA-Bw4 pres

32

23.7

74

33.5

 KIR3DS1 pres/HLA-Bw4 abs

21

15.5

14

6.3

0.006

2.7 (1.27–5.9)

Inhibitory KIR and their ligands

 KIR2DL1 pres/HLA-C2 pres

100

74.1

164

74.2

 KIR2DL1 pres/HLA-C2 abs

32

23.7

51

23.1

 KIR2DL2 pres/HLA-C1 pres

47

34.8

83

37.6

 KIR2DL2 pres/HLA-C1 abs

32

23.7

43

19.5

 KIR2DL3 pres/HLA-C1 pres

78

57.8

132

59.7

 KIR2DL3 pres/HLA-C1 abs

45

33.3

56

25.3

 KIR3DL1 pres/HLA-Bw4 pres

90

63.7

159

71.9

 KIR3DL1 pres/HLA-Bw4 abs

45

33.3

47

21.3

0.013

1.9 (1.1–3.1)